ROIV ▲ +2.6% - Roivant Sciences Ltd. $ROIV ROIVW - Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Roivant Sciences rose 2.6% following news that it will present Phase 2 topline results for mosliciguat, its pulmonary hypertension treatment candidate, at the European Respiratory Society Congress in September 2026, along with hosting an investor call. The presentation of clinical data from this late-stage study appears to have bolstered investor sentiment around the company's pipeline progress. 06-SEP-2026 01:00 AM ET